The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials.

PURPOSE

Several meta-analyses reported berberine (BBR) supplementation improves glycemic parameters and inflammatory marker, but findings remain inconsistent. Therefore, this study was conducted.

METHODS

We systematically searched PubMed, Embase, Web of Science, Scopus, and Google Scholar to identify the relevant meta-analyses up to April 2023.

FINDINGS

BBR supplementation was effective in reducing fasting blood glucose (FBG) (ES: -0.77; 95% CI: -0.90 to -0.63, and ES: -0.65; 95% CI: -0.83 to -0.47), hemoglobin A1C (HbA1C) (ES: -0.57; 95% CI: -0.68 to -0.46), homeostasis model assessment for insulin resistance (HOMA-IR) (ES: -1.04; 95% CI: -1.66 to -0.42, and ES: -0.71; 95% CI: -0.97 to -0.46), insulin (ES: -1.00; 95% CI: -1.70 to -0.30, and ES: -0.63; 95% CI: -0.94 to -0.32), interleukin (IL)-6 (ES: -1.23; 95% CI: -1.61 to -0.85), tumor necrosis factor-α (TNF-α) (ES: -1.04; 95% CI: -1.28 to -0.79), and C-reactive protein (CRP) (ES: -0.62; 95% CI: -0.74 to -0.50, and ES: -1.70; 95% CI: -2.21 to -1.19).

IMPLICATIONS

The finding of our umbrella showed that the supplementation of BBR could be effective in improving glycemic parameters and inflammatory marker in adults.